Empowered Funds LLC Makes New $12.05 Million Investment in Humana Inc. $HUM

Empowered Funds LLC bought a new position in shares of Humana Inc. (NYSE:HUM) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 30,339 shares of the insurance provider’s stock, valued at approximately $12,051,000.

Other institutional investors have also recently added to or reduced their stakes in the company. United Capital Financial Advisors LLC acquired a new position in Humana in the 2nd quarter valued at about $2,580,000. Equitable Holdings Inc. acquired a new stake in Humana during the 2nd quarter worth approximately $282,000. Centaurus Financial Inc. purchased a new position in shares of Humana in the 2nd quarter valued at approximately $199,000. Jefferies Financial Group Inc. purchased a new position in shares of Humana in the 2nd quarter valued at approximately $701,000. Finally, Public Employees Retirement System of Ohio acquired a new position in shares of Humana in the second quarter valued at approximately $24,784,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Trading Down 1.5%

NYSE:HUM opened at $386.92 on Friday. The stock has a fifty day moving average price of $385.60 and a two-hundred day moving average price of $288.47. The stock has a market capitalization of $46.46 billion, a price-to-earnings ratio of 36.61, a PEG ratio of 2.20 and a beta of 0.72. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.74 and a current ratio of 1.74. Humana Inc. has a 1 year low of $163.11 and a 1 year high of $428.88.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, July 29th. The insurance provider reported $7.61 EPS for the quarter, topping the consensus estimate of $7.27 by $0.34. Humana had a net margin of 0.88% and a return on equity of 11.20%. The company had revenue of $40.89 billion for the quarter, compared to analyst estimates of $40.58 billion. During the same period in the previous year, the firm earned $6.27 EPS. The business’s revenue was up 26.2% on a year-over-year basis. As a group, sell-side analysts anticipate that Humana Inc. will post 9.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

HUM has been the subject of several recent research reports. Wolfe Research reaffirmed an “outperform” rating and set a $450.00 price target on shares of Humana in a report on Monday, August 24th. Lake Street Capital began coverage on shares of Humana in a research note on Thursday, July 30th. They issued a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Humana in a research report on Thursday, July 30th. They set a “hold” rating for the company. HSBC downgraded shares of Humana to a “hold” rating in a report on Thursday, July 30th. Finally, Oppenheimer reiterated an “outperform” rating and set a $405.00 price target on shares of Humana in a research note on Thursday, July 30th. Fourteen equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $403.91.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.